FR3096264B1 - Procédé de préparation de compositions pharmaceutiques contenant des principes actifs amphiphiles - Google Patents

Procédé de préparation de compositions pharmaceutiques contenant des principes actifs amphiphiles Download PDF

Info

Publication number
FR3096264B1
FR3096264B1 FR1905539A FR1905539A FR3096264B1 FR 3096264 B1 FR3096264 B1 FR 3096264B1 FR 1905539 A FR1905539 A FR 1905539A FR 1905539 A FR1905539 A FR 1905539A FR 3096264 B1 FR3096264 B1 FR 3096264B1
Authority
FR
France
Prior art keywords
preparation
pharmaceutical compositions
compositions containing
active principles
amphiphilic active
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
FR1905539A
Other languages
English (en)
Other versions
FR3096264A1 (fr
Inventor
François Fauran
Didier Muller
Jean-Luc Barnoux
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pharmadev SA
Original Assignee
Pharmadev SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmadev SA filed Critical Pharmadev SA
Priority to FR1905539A priority Critical patent/FR3096264B1/fr
Priority to MA056024A priority patent/MA56024A/fr
Priority to PCT/EP2020/064345 priority patent/WO2020239645A1/fr
Priority to EP20728902.6A priority patent/EP3975998A1/fr
Priority to US17/614,076 priority patent/US20220378705A1/en
Publication of FR3096264A1 publication Critical patent/FR3096264A1/fr
Application granted granted Critical
Publication of FR3096264B1 publication Critical patent/FR3096264B1/fr
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1611—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Emergency Medicine (AREA)
  • Inorganic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)

Abstract

Procédé de préparation de compositions pharmaceutiques contenant des principes actifs amphiphiles La présente invention concerne un procédé de granulation d’un principe actif amphiphile, ou d’un sel pharmaceutiquement acceptable de celui-ci, comprenant une étape d’enrobage du principe actif dans un solvant aprotique polaire en présence d’un liant polymérique, pour obtenir un granulé.
FR1905539A 2019-05-24 2019-05-24 Procédé de préparation de compositions pharmaceutiques contenant des principes actifs amphiphiles Active FR3096264B1 (fr)

Priority Applications (5)

Application Number Priority Date Filing Date Title
FR1905539A FR3096264B1 (fr) 2019-05-24 2019-05-24 Procédé de préparation de compositions pharmaceutiques contenant des principes actifs amphiphiles
MA056024A MA56024A (fr) 2019-05-24 2020-05-23 Procédé de préparation de compositions pharmaceutiques contenant des principes actifs amphiphiles
PCT/EP2020/064345 WO2020239645A1 (fr) 2019-05-24 2020-05-23 Procédé de préparation de compositions pharmaceutiques contenant des principes actifs amphiphiles
EP20728902.6A EP3975998A1 (fr) 2019-05-24 2020-05-23 Procédé de préparation de compositions pharmaceutiques contenant des principes actifs amphiphiles
US17/614,076 US20220378705A1 (en) 2019-05-24 2020-05-23 Method for preparing pharmaceutical compositions containing amphiphilic active ingredients

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR1905539 2019-05-24
FR1905539A FR3096264B1 (fr) 2019-05-24 2019-05-24 Procédé de préparation de compositions pharmaceutiques contenant des principes actifs amphiphiles

Publications (2)

Publication Number Publication Date
FR3096264A1 FR3096264A1 (fr) 2020-11-27
FR3096264B1 true FR3096264B1 (fr) 2022-01-07

Family

ID=68806831

Family Applications (1)

Application Number Title Priority Date Filing Date
FR1905539A Active FR3096264B1 (fr) 2019-05-24 2019-05-24 Procédé de préparation de compositions pharmaceutiques contenant des principes actifs amphiphiles

Country Status (5)

Country Link
US (1) US20220378705A1 (fr)
EP (1) EP3975998A1 (fr)
FR (1) FR3096264B1 (fr)
MA (1) MA56024A (fr)
WO (1) WO2020239645A1 (fr)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0297866A3 (fr) * 1987-07-01 1989-12-13 The Boots Company PLC Agents thérapeutiques
CA2068402C (fr) * 1991-06-14 1998-09-22 Michael R. Hoy Enrobage pour masquer le gout pouvant etre utilise dans des comprimes pharmaceutiques croquables
US20090186086A1 (en) * 2008-01-17 2009-07-23 Par Pharmaceutical, Inc. Solid multilayer oral dosage forms
US10668156B2 (en) * 2012-06-22 2020-06-02 Basf Se Active-ingredient-containing solid dispersions based on diethylaminoethyl methacrylate copolymers

Also Published As

Publication number Publication date
FR3096264A1 (fr) 2020-11-27
EP3975998A1 (fr) 2022-04-06
MA56024A (fr) 2022-04-06
WO2020239645A1 (fr) 2020-12-03
US20220378705A1 (en) 2022-12-01

Similar Documents

Publication Publication Date Title
CR20210045A (es) Inhibidores de inflamasoma nlrp3
Suneja et al. Enantioselective hydrophosphonylation of in situ generated N-acyl ketimines catalyzed by BINOL-derived phosphoric acid
MA46997B1 (fr) Préparation de complexes solides de cyclodextrine permettant une administration de substance pharmaceutique active ophtalmique
JOP20210307A1 (ar) مثبطات جسيم التهابي nlrp3
EA201990851A1 (ru) Новые аналоги карбануклеозида, замещенные моноциклической и бициклической кольцевой системой, для применения в качестве ингибиторов prmt5
Lu et al. Application of “hydrogen bonding interaction” in new drug development: Design, synthesis, antiviral activity, and SARs of thiourea derivatives
Kucherenko et al. C2-symmetric chiral squaramide, recyclable organocatalyst for asymmetric Michael reactions
MA47469B1 (fr) Dérivés 2-(3-(1h-benzo[d]imidazol-1-yl)propyl)pipéridin-3-ol et composés similaires en tant q'inhibiteurs prs pour le traitement du cancer
EA202090573A1 (ru) Составы нирапариба
WO2020016749A3 (fr) Procédé chimique pour la préparation de dérivés de phénylpipéridinyl indole
MA38397A1 (fr) Agglomérats inhalables de particules de support poreuses et médicament micronisé
EP4249070A3 (fr) Dérivés hétéroaryle bicycliques utilisés en tant qu'inhibiteurs de l'ectonucléotide pyrophosphatase/phosphodiestérase 1
Ferraris et al. δ-Thiolactones as prodrugs of thiol-based glutamate carboxypeptidase II (GCPII) inhibitors
MA35411B1 (fr) Nouvelle composition thérapeutique contenant de l'apomorphine comme principe actif
EP3201194B1 (fr) Sels de composés ayant une structure benzimidazolique, leurs utilisations et procédé de préparation
MA46608B1 (fr) Formulation liposomale utile pour le traitement du cancer
MA39983A (fr) Dérivés de carboxamide
EA200901146A1 (ru) Твердые лекарственные формы, содержащие алискирен и его фармацевтически приемлемые соли
López-Francés et al. Exploring the synthetic potential of γ-lactam derivatives obtained from a multicomponent reaction—Applications as antiproliferative agents
FR3096264B1 (fr) Procédé de préparation de compositions pharmaceutiques contenant des principes actifs amphiphiles
MA41174B1 (fr) Dérivés d'imidazopyridazine utilisés en tant qu'inhibiteurs de pi3kbeta
EA202092062A1 (ru) Фармацевтическая композиция, содержащая брекспипразол
MA46778A1 (fr) Composition intranasale comprenant de la bétahistine
EP3404020A4 (fr) Dérivé de pyridinol ou sel pharmaceutiquement acceptable de celui-ci, et composition pharmaceutique contenant celui-ci utilisé comme principe actif
Leahy et al. Preparation of phosphonooxymethyl prodrugs of HIV-1 attachment inhibitors

Legal Events

Date Code Title Description
PLFP Fee payment

Year of fee payment: 2

PLSC Publication of the preliminary search report

Effective date: 20201127

PLFP Fee payment

Year of fee payment: 3

PLFP Fee payment

Year of fee payment: 4

PLFP Fee payment

Year of fee payment: 5

PLFP Fee payment

Year of fee payment: 6

PLFP Fee payment

Year of fee payment: 7